• Journal
  • General Interest
  • Pulmonary
As fossil fuel combustion continues to power the global economy, the rate of climate change is accelerating, causing severe respiratory health impacts and large disparities in the degree of human s
0
  • 1.00 AMA PRA Category 1 Credit(s)
  • 1.00 Participation
  • Journal
  • General Interest
  • Pulmonary
Pulmonary hypertension, frequently complicating the course of patients with fibrotic interstitial lung disease, is associated with significantly increased morbidity and mortality.
0
  • 1.00 AMA PRA Category 1 Credit(s)
  • 1.00 Participation
  • Journal
  • General Interest
  • Pulmonary
Hypoxemic respiratory failure is one of the leading causes of mortality in intensive care.
0
  • 1.00 AMA PRA Category 1 Credit(s)
  • 1.00 Participation
  • Journal
  • General Interest
  • Pulmonary
Lung health, the development of lung disease, and how well a person with lung disease is able to live all depend on a wide range of societal factors.
0
  • 1.00 AMA PRA Category 1 Credit(s)
  • 1.00 Participation
  • Journal
  • General Interest
  • Pulmonary
In study after study, marijuana use has been found to be associated with increased forced vital capacity (FVC).
0
  • 1.00 AMA PRA Category 1 Credit(s)
  • 1.00 Participation
  • Journal
  • General Interest
  • Pulmonary
Chronic obstructive pulmonary disease (COPD) is a major public health problem in the Americas (a region of the world comprising North, Central, and South America), although there is substantial var
0
  • 1.00 AMA PRA Category 1 Credit(s)
  • 1.00 Participation
  • Journal
The definition of pulmonary hypertension (PH) has been revised recently, with the mean pulmonary artery pressure (mPAP) threshold (assessed by right heart catheterization) reduced from ≥25mm Hg to
0
  • 1.00 AMA PRA Category 1 Credit(s)
  • 1.00 Participation
  • Journal
  • General Interest
  • Pulmonary
Alpha-1 antitrypsin deficiency (AATD) is an underrecognized condition with only a small minority of affected individuals diagnosed, long delays between initial symptoms and diagnosis, and evidence
0
  • 1.00 AMA PRA Category 1 Credit(s)
  • 1.00 Participation
  • Journal
  • General Interest
  • Pulmonary
An evidence-based guideline for the treatment of patients with systemic sclerosis–associated interstitial lung disease (SSc-ILD) was created in 2023 by a panel of multidisciplinary experts. 
0
  • 1.00 AMA PRA Category 1 Credit(s)
  • 1.00 Participation

Pages